MEDI-528, now recognized as enokiizumab , represents a novel medication targeting the insulin-like growth factor 1 receptor , a crucial protein implicated in multiple epidermal conditions . Early trial https://cyruspcqu778568.blogdigy.com/enokizumab-a-deep-dive-into-medi-528-and-its-potential-65776692